2016 - Cristal Therapeutics

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

6th December 2016/in News /by Alex Jones

Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016 – Cristal Therapeutics, a Dutch privately-held life sciences company developing novel nanomedicines against cancer and other […]

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

29th April 2016/in News /by Alex Jones

Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He will be responsible for the clinical strategy and development of Cristal Therapeutics’ range of nanomedicines. […]